| Nov 15 |
Dare Bioscience files to sell 2.75M shares of common stocks by selling shareholders
|
| Nov 15 |
Q3 2024 Dare Bioscience Inc Earnings Call
|
| Nov 15 |
Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...
|
| Nov 15 |
Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript
|
| Nov 14 |
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates
|
| Nov 14 |
Dare Bioscience GAAP EPS of -$0.55 beats by $0.14, revenue of $41.69M beats by $39.67M
|
| Nov 14 |
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
|
| Nov 14 |
Earnings Scheduled For November 14, 2024
|
| Nov 13 |
Dare Bioscience Q3 2024 Earnings Preview
|
| Nov 13 |
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites
|
